NCT06514118

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

Chemoimmunotherapy Plus Ratiotherapy for Extensive Stage Small-cell Lung Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 70 (estimated)
• Sponsor: Qingdao Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate the progression-free survival (PFS) and overall survival of chemoimmunotherapy sequential residual tumor irradiation in patients with extensive stage small cell lung cancer (SCLC). SECONDARY OBJECTIVES: II. To assess the overall response rate (ORR) and toxicity in extensive stage SCLC patients treated with chemoimmunotherapy squential residual tumor irradiation

Conditions

• Small-cell Lung Cancer
• Residual Tumor
• Radiation

Interventions

Type	Name	Description
RADIATION	residual tumor irradiation	lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total

Timeline

• Start date: 2024-04-17
• Primary completion: 2026-03-16
• Completion: 2027-03-16
• First posted: 2024-07-23
• Last updated: 2024-07-23

Locations

3 sites across 1 country: China